Skip to content

Study evaluating hysteroscopic removal of uterine lining as a treatment for heavy menstrual bleeding in pre-menopausal women.

TRANSCERVICAL RESECTION OF ENDOMETRIUM AS A CONSERVATIVE MANAGEMENT OF ABNORMAL UTERINE BLEEDING IN PREMENOPAUSAL WOMEN PROSPECTIVE CROSS SECTIONAL INTERVENTIONAL STUDY - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/106603
Enrollment
55
Registered
2026-03-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N924- Excessive bleeding in the premenopausal period

Interventions

Intervention1: Transcervical resection of endometrium: Hysteroscopic guided transcervical resection of endometrium done for patients with abnormal uterine bleeding. Control Intervention1: NIL: NIL

Sponsors

Karnataka medical college and research institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All women presenting to KMCRI gynecology OPD with diagnosis of abnormal uterine bleeding- Failed medical management Medical management was contraindicated or had adverse effects of it. (previous history of deep venous thrombosis, thromboembolism, liver disease) Cases who are unfit for hysterectomy Cases not willing for hysterectomy Young women (less than 35 years) with completed family.

Exclusion criteria

Exclusion criteria: Women with the following features were excluded from the study- Women who want to retain fertility Acute genital tract infections Adenomyosis Uterine size greater than 12 weeks/ cavity greater than 12 cm Fibroids and other structural malformations Abnormal endometrial and cervical cytology. Patients with prior surgery like classical Caesarean section and myomectomy

Design outcomes

Primary

MeasureTime frame
To analyse the effect on bleeding symptoms at 6 weeks, 3 months, 6 months and 1 year.Timepoint: To analyse the effect on bleeding symptoms at 6 weeks, 3 months, 6 months and 1 year.

Secondary

MeasureTime frame
Patient satisfaction and those requiring additional treatment was assessed.Timepoint: followed up for 6 months

Countries

India

Contacts

Public ContactKeerthana M U

Karnataka medical college and research institute

svn1974@gmail.com9343882242

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026